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Background: Bleomycin hydrolase (BH) is a cysteine protease that is found in all
tissues in mammals as well as in many other eukaryotes and prokaryotes.
Although its conserved cellular function is as yet unknown, human bleomycin
hydrolase (hBH) has clinical significance in that it is thought to be the major cause
of tumor cell resistance to bleomycin chemotherapy. In addition, it has been
reported that an allelic variant of hBH is genetically linked to Alzheimer’s disease.
Results: We have determined the crystal structures of wild-type hBH and of a
mutant form of the enzyme. The overall structure is very similar to that of the
previously determined yeast homolog, however, there is a striking difference in
the charge distribution. The central channel, which has a strong positive
electrostatic potential in the yeast protein, is slightly negative in hBH. We have
determined that hBH does not have the DNA-binding activity of the yeast
protein and that the enzyme is localized to the cytoplasm.
Conclusions: The difference in charge distribution between the yeast and
human BH enzymes is most likely responsible for the difference in DNA-binding
activity. Nevertheless, the C-terminal autoprocessing activity and the role of the
C terminus as a determinant for peptidase activity are conserved between the
yeast and human forms. The structure of hBH suggests that the putative
Alzheimer’s disease linked variation does not directly alter the intrinsic
peptidase activity. Rather, the position of the mutation suggests that it could
affect interactions with another protein, which may modulate peptidase activity
through repositioning of the C terminus.
Introduction
Bleomycin hydrolase (BH) is a cysteine protease with
unusual structural and biological features. The enzyme was
discovered due to its ability to deactivate the glycopeptide
antibiotic, bleomycin, which is used as a therapeutic agent
in the treatment of a number of forms of cancer. This
endogenous enzyme is overexpressed in some tumor cells
and is thought to be a major cause of tumor cell resistance
to bleomycin therapy [1]. Studies on BH knockout mice
indicated that BH is important for neonatal survival [2]. In
addition, these studies showed that in mammalian cells BH
is the only enzyme with bleomycin deamidation activity.
Interest in the clinical relevance of BH was heightened by
a recent report of the genetic linkage of an allelic variant to
Alzheimer’s disease (AD) [3].
BH is widely distributed throughout nature with
homologs found in bacteria [4–9], yeast [10–13], amphib-
ians [14], birds [15] and mammals [16–18]. Its expression
in animals does not appear to be tissue-specific. There is
high sequence identity between the different forms of BH
with, for example, the yeast form exhibiting 35% and 41%
identity with the bacterial and human forms, respectively.
The evolutionary conservation and wide distribution of
the enzyme suggests that it has a conserved cellular func-
tion. This function has yet to be elucidated, however. The
enzyme has been named bleomycin hydrolase as isolated
from mammalian cells for its capacity to detoxify
bleomycin, and Gal6 from yeast for its ability to regulate
the galactose inducible genes.
The crystal structure of the yeast BH, Gal6, has been
solved and reveals a hexameric ring barrel structure with
the active sites embedded in a central cavity [19]. This
cavity is 22 Å wide at the openings at either end, and
widens to 45 Å in the interior of the protein. The only
access to the active sites is through the cavity, and thus a
protein substrate would need to be at least partially
unfolded or degraded in order to reach them. BH has little
substrate specificity so it is reasonable to assume that this
sequestration of the active sites is necessary to prevent
indiscriminate proteolysis. This places BH in the class of
‘self-compartmentalizing proteases’ with, for example, the
proteosome and the tricorn protease [20,21]. The C termi-
nus of Gal6 lies in the active site, in much the same posi-
tion as that taken by inhibitors in complex with the
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protease papain. Recent work on Gal6 has shown that the
enzyme acts as a carboxypeptidase on its own C terminus
to convert itself to an aminopeptidase and peptide ligase
[22]. The C terminus anchors the substrate into the active
site and confers ‘positional’ specificity. This model also
serves to explain the singular ability of Gal6 to inactivate
bleomycin. In addition to the protease activity, at least
some members of the BH family have a nucleic acid
binding activity. The yeast form of BH strongly binds
RNA, single-stranded DNA and nicked double-stranded
DNA [13,23].
In view of the clinical relevance of this protein, we have
determined the crystal structures of wild-type human BH
(hBH) and of a mutant form of the enzyme. We have also
examined the nucleic acid binding activity and cellular
localization of hBH in comparison to the yeast form, in an
attempt to gain further insight into the conserved cellular
functions of the enzyme.
Results and discussion
The overall structure
The structure of hBH is presented in Figure 1. Both the
wild-type and mutant structures were solved by molecular
replacement, using Gal6 as a search model, and refined to
2.6 Å and 1.85 Å resolution, respectively. Crystallographic
statistics are reported in Table 1. The structure of hBH was
expected to be very similar to that of the yeast form due to
the sequence similarity. Superpositions between the
monomers and the hexamers of the yeast and human pro-
teins are shown in Figure 2a. The root mean square (rms)
deviation of Cα atoms is 1.23 Å between two monomers
and 1.43 Å between two hexamers. It has been suggested
[24] that the low sequence similarity between the N-termi-
nal domains of the yeast and human enzymes implies struc-
tural divergence at the N terminus, which in turn could
result in hBH forming a tetramer rather than the hexamer
formed by Gal6. We find, however, that the structures are
very similar even in this region, with the exception of the
first six residues which point in different directions.
The C terminus
The C terminus of Gal6 is flexible, allowing it to rotate
and move in the active-site cleft. This flexibility defines
the enzymatic activity of the protein by controlling the
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Figure 1
The structure of hBH. The six subunits are
shown in different colors. (a) Top view of the
hexamer down the threefold axis. Dimer
interactions occur between the top and
bottom subunits (between the red and blue,
yellow and purple, and orange and green
subunits). (b) Side view, with the hexamer
rotated 90° about the y axis. The dimer
interactions are clearly visible, with the so-
called ‘hook’ domains of the yellow and blue
subunits hooking over the purple and red
subunits, respectively. (The figure was
prepared with the programs Bobscript [41],
Molscript [42] and Raster3D [43].)
Table 1
Crystallographic data and refinement statistics.
Protein Wild type Cys73→Ser/∆Glu455
Space group C2221 R32
Cell dimensions (Å)
a,b,c 133.3, 171.5, 145.7 179.5*, 179.5, 164.2
Monomers per 
asymmetric unit 3 2
Resolution (Å) 25–2.59 25–1.85
No. of reflections
observed 242,494 317,648
unique 47,632 77,497
Rsym (%)
overall/last shell 7.2/43.1† 8.2/25.9‡
Completeness (%)
overall/last shell 91.6/94.0† 89.9/87.4‡
I/σI
overall/last shell 18.8/3.5† 20.3/3.5‡
Rcryst (%)
overall/last shell 23.8/30.4§ 18.2/21.1#
Rfree (%)
overall/last shell 26.1/32.1§ 21.0/24.2#
Rmsd bond angles (°) 1.3 1.6
Rmsd bond lengths (Å) 0.007 0.013
Average B factor (Å2) 39.1 22.0
Residues in allowed region
of Ramachandran plot (%) 99.0 99.3
No. of protein atoms 11,022 7348
No. of water molecules – 563
*Cell dimensions given for the R32 space group are for the hexagonal
setting. Values for the highest resolution shells are given:
†2.68–2.59 Å; ‡1.92–1.85 Å; §2.75–2.59 Å; #1.97–1.85 Å.
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Figure 2
Comparison of the human and yeast BH
enzymes. (a) Superposition of hBH on yeast
Gal6. The left and right panels show
superimposed hexamers and monomers,
respectively. The structures are shown as Cα
traces, with the human protein shown in red
and the yeast protein in green. The structures
were superimposed using a least-squares
alignment based on the conserved sequences
around the active-site residues. (b) Alignment
of the human (hBH) and yeast BH (Gal6)
amino acid sequences. Identical residues are
highlighted in green, with asterisks marking
the active-site residues. Secondary structure
motifs are colored according to domain: the
hook domain is in red; the core papain-like
domain is in green; the helical domain is in
blue; and the C-terminal region is in pink.
Residues are numbered according to the
human sequence. (c) GRASP [44]
representations of the electrostatic surface
potential for hBH and Gal6. The color scheme
depicts potentials < –10 kBT in red and
> 10 kBT in blue, where kB is the Boltzmann
constant and T is the absolute temperature.
For this calculation, the dielectric constants
were 80 for the solvent and 2 for the protein;
the ionic strength was 0. The top panels show
hBH and the lower panels show Gal6. The left
panels show a top view down the threefold
axis; the panels on the right show a slice
through the protein approximately along the
threefold axis, highlighting the difference in
charge between interiors of the human and
yeast proteins.
position of the C terminus in the active site [22]. It is this
control that determines the diverse potential activities of
Gal6. In Gal6 the C-terminal amino acid is encoded as
lysine. This  residue is removed in an autocatalytic reac-
tion, truncating the protein at the end of the conserved
eight-residue C-terminal sequence that is found in all BH
enzymes. The corresponding residue in the human
protein is glutamic acid. In spite of the difference in
charge, we find that the glutamic acid residue in hBH is
also removed, implying that the carboxypeptidase activity
of BH is charge insensitive.
In order to determine if hBH displays the same flexibility
of the C terminus as the yeast enzyme, we solved the
structure of a mutant in which the active-site cysteine was
converted to serine (Cys73→Ser/∆Glu455). As this alter-
ation abolishes the peptidase activity of the protein (see
Materials and method section), the terminal glutamic acid
(Glu455) was genetically removed to produce an authentic
C terminus. Apart from the C-terminal arm, the structures
of the wild-type and the mutant proteins are virtually
identical, with an rms deviation for Cα atoms of 0.25 Å,
even though they belong to different crystal forms and
thus undergo different packing interactions. In a similar
fashion to the Cys73→Ala/∆Lys454 mutant of Gal6 [22],
Ala454 of the hBH mutant moves further towards the
active site to occupy the P1 position (for nomenclature see
[25,26]), which is open in the wild-type protein (Figure 3).
In hBH, Gly451, which is the equivalent of Gly450 in
yeast, also allows the chain to rotate and extend at that
point by a screw-like movement to allow this repositioning
of the C terminus. However, in this case it is a serine
rather than an alanine that replaces the nucleophilic cys-
teine, Cys73. In order for this movement to take place,
Met370 moves out of the way of the repositioned Leu453.
In addition, the hydroxyl group of Ser73, which as cys-
teine in the wild-type protein is somewhat mobile and
moves between positions where it either interacts with the
carbonyl of residue 71 or with the amide of residue 373, is
hydrogen bonded to the amide of residue 373. One of the
C-terminal carboxylate oxygens interacts both with the
amide of Ser73 and with Gln67 in the oxyanion hole, and
the other interacts with the amide group of Trp74. It
appears that the choreography of the C terminus has been
conserved between the yeast and human forms of BH.
Human versus yeast BH
The most striking difference between the yeast and
human forms of BH is the charge distribution. Although
the overall charge of the yeast protein is neutral, the
central channel is lined with 60 lysine residues and as a
result has a strong positive electrostatic potential (see
Figure 2c; bottom). This charge distribution suggested
that the central channel was the site of nucleic acid
binding. The mutation to alanine of three lysine residues
from each monomer that are found at the entrance to the
channel abolished the nucleic acid binding activity [23].
Although this mutation did not affect Gal6 activity in vitro,
yeast cells expressing only the non-DNA-binding protein
had much reduced resistance to bleomycin, indicating that
the nucleic acid binding activity does have a role in
bleomycin detoxification in yeast in vivo [27]. In hBH, two
of the corresponding lysine residues of the yeast protein
are present, whereas the third is an asparagine. However,
hBH has a slightly negative electrostatic potential in the
channel (see Figure 2c; top). The calculated pI for hBH is
6.0. Whether or not mammalian BH binds DNA or RNA is
controversial: it has been reported that the rat form from
cell extracts does bind DNA [18], whereas the human
form produced in Escherichia coli does not [16,24]. Interest-
ingly, the bacterial BH, PepC, which has a calculated pI of
4.8 for the hexamer, does bind single-stranded DNA (HE
Xu and SAJ, unpublished data). It should be noted that
the yeast BH, Gal6, is the only member of the family
known to date to have a basic pI.
DNA binding and cellular localization
A gel shift assay was employed to determine if hBH binds
nucleic acid. As evident in Figure 4a, the yeast form of BH
binds a single-stranded oligonucleotide avidly, but there is
no evidence of binding in the human cell extracts. Enzyme
assays (Figure 4a) and a western blot attest to the presence
of the human protein in the cell extracts at a level compara-
ble to that of the yeast protein. A mixing experiment
(Figure 4a; lane 7) in which yeast protein was added to the
human cell extract demonstrates that the extract is not
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Figure 3
The C terminus of hBH. Residues 447–454 of the wild-type protein, as
well as the catalytic Cys73, are shown as bonds colored according to
atom type. The corresponding residues of the Cys73→Ser/∆Glu455
mutant protein are shown in cyan. The sidechains of the catalytic
residues His372 and Asp396 are shown with yellow bonds, as is the
sidechain of Gln67, which stabilizes the oxyanion intermediate during
catalysis. Hydrogen-bond interactions of the mutant protein — between
the C-terminal alanine and the sidechain of Gln67 and the amide
nitrogen atoms of Ser73 and Trp74, and between Ser73 and the
backbone amide of residue 373 — are shown as dotted white lines.
Arrows indicate the Cα atoms of labeled residues. Gly451 is the
elbow at which the C-terminal arm rotates and extends.
inhibitory. We conclude that hBH does not have the
nucleic acid binding properties of Gal6. As pointed out
above, hBH only has two of the three lysine residues at the
entrance of the channel which are required for nucleic acid
binding by Gal6. This is not sufficient to explain the differ-
ence in binding, however, as the bacterial and rat forms of
BH, both of which have nucleic acid binding activity, also
have only one or two of these lysines, respectively. Appar-
ently, the nucleic acid binding activity also involves other
sequences. Immunolocalization studies indicate that the
yeast form of BH is largely localized to the cytoplasm and
excluded from the nucleus [27]; hBH also appears to be
largely cytoplasmic with relative exclusion of localization in
the nucleus (Figure 4b). This suggests that the human and
yeast proteins not only have the same structure, but may
also perform the same cellular functions.
hBH and Alzheimer’s disease
The β-amyloid peptide (Aβ) associated with Alzheimer’s
disease (AD) is a peptide of 40–42 amino acids derived
from the amyloid precursor protein (APP) and accumu-
lates in the amyloid plaques of both ‘sporadic’ and familial
cases of AD [28]. Aβ is thought to be produced by prote-
olytic processing by a β-secretase at its N terminus and a
γ-secretase at its C terminus, both of which have yet to be
identified. A cysteine protease purified from AD brain by
virtue of its ability to cleave a synthetic peptide encom-
passing the β-secretase cleavage site was found to associ-
ate with APP [29] and later identified as hBH
(C Abraham, personal communication). Recently, it was
reported that there is a genetic linkage of an allelic variant
of hBH to the non-familial form of AD [3], although a sub-
sequent study on a different population failed to detect
the same association [30]. This may or may not relate to
APP processing directly. The disease-linked form of hBH
has a valine at position 443, as opposed to an isoleucine in
the other isoform. Interestingly, Gal6, also has valine at
this position. In addition, this is one region that shows
divergence between the yeast and human proteins, with
the loop preceding residue 443 being quite different in
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Figure 4
Nucleic acid binding and cellular localization
of hBH. (a) Gel mobility shift assay
demonstrating that hBH in whole cell extracts
(WCE) does not bind nucleic acid. A single-
stranded DNA oligonucleotide was incubated
with either 30 mg WCE from wild-type yeast
or from HeLa cells, or with 700 ng
recombinant hBH produced in E. coli. A
mixing experiment was performed
(HeLa + yGal6) in which 150 ng recombinant
Gal6 was added to the HeLa extract in order
to demonstrate that the extract conditions
were not inhibitory. Lanes designated by a (+)
indicate samples in which 20 µg of rabbit anti-
hBH IgG was included following the binding
reaction to visualize a supershift of the
DNA–protein band. To the right of the gel
shift is a western blot for hBH of the same
WCE preparations used in the gel shift. The
relative specific activities of hBH and Gal6
present in the WCE used for the gel-shift
experiments were 21.6 and 23.2, respectively.
Measurements reflect the specific hydrolysis
of a fluorogenic substrate and demonstrate
that equivalent amounts of specific enzyme
activity were incorporated into the hBH and
Gal6 DNA-binding reactions.
(b) Immunolocalization of hBH within HeLa
cells. The left panel shows hBH localized to
the cytoplasm. The right panel shows a
control experiment where the primary anti-
hBH antibody was omitted. The scale bar in
each panel represents 15 µm.
structure. This loop is not involved in any crystal contacts
in any of the three crystal forms. It appears that the differ-
ences in conformation in this region are largely due to a
three-residue insertion five residues N-terminal to this
isoleucine. In fact, for the residues following Ile443, the
polypeptide chains track each other again very closely.
Residue 443 sits at the edge of a charged cleft on the
surface of the molecule. Five residues C-terminal to this
isoleucine is Trp447, which is part of the conserved C-ter-
minal arm. Trp447 is involved in a four-residue stacking
interaction with Arg131 and their counterparts in the
dimer-related subunit (Figure 5). The chain is then
inserted into the barrel of the protein and descends into
the active-site cleft. As the sidechain of this isoleucine
residue does not appear to be involved in any intramolecu-
lar or any monomer–monomer interactions, or even in any
crystal contacts, it is unlikely that removing a methyl
group, as would be the case for a valine substitution,
would affect the protein conformation per se. We have pre-
viously suggested that the activity of Gal6 could be con-
trolled by interaction with a protein that altered the
position of the C-terminal arm [19], and have shown that
the positioning of the C terminus has profound effects on
the enzymatic activity of Gal6 [22]. The region around
residue 443 is a likely candidate for interaction with such a
regulatory protein. As the I/V polymorphism associated
with AD is not expected to substantially change the struc-
ture of hBH, we suggest that if it does have a biological
effect this probably arises from modifications in the inter-
action of hBH with another protein.
Biological implications
The clinical use of bleomycin is limited due to drug resis-
tance [1,31] and dose-dependent production of pul-
monary fibrosis [32]. Resistance to antineoplastic drugs,
whether intrinsic or acquired, is a major problem in the
treatment of human cancers. Bleomycin hydrolase (BH)
was shown to be a cysteine protease that detoxifies
bleomycin by hydrolysis of the amide bond in the
β-aminoalanine moiety, producing inactive metabolites
[33]. This appears to limit the effectiveness of the drug,
as cancer cells with increased expression of BH are
resistant to drug treatment. In addition, tissues with nat-
urally low levels of BH, such as skin and lung, are par-
ticularly sensitive to bleomycin [34] and it was recently
shown that in mammalian cells BH is the only enzyme
with bleomycin deamidation activity [2].
As mammals rarely encounter bleomycin, bleomycin
hydrolysis is probably not the normal function of the
enzyme. Studies with BH knockout mice have shown
that BH is important for neonatal survival [2]. BH is
widely distributed throughout nature with homologs
found in bacteria, yeast, birds and mammals; the different
forms of BH exhibit high sequence identity. The yeast
form of BH, Gal6, negatively regulates the galactose
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Figure 5
The 440’s loop. (a) Residues 442–447 and residue 131 of the blue
subunit are shown as bonds colored according to atom type. This loop
contains Ile443; the Val443 isoform has been implicated in Alzheimer’s
disease (see text). C-terminal of IIe443 is Trp447, which forms a four-
residue stack with Arg131 of the same subunit and the corresponding
residues, shown in yellow, of the dimer-related red subunit. The
C-terminal arm, also shown in yellow, then descends into the active-
site cleft. Arrows indicate the Cα atom of Trp447 and the Cγ atom of
Ile443, which is missing in the valine variant. (b) The boxed area shows
the position of the 440’s loop in hBH. This is one of six identical
regions found in the hexamer containing the polymorphism associated
with Alzheimer’s disease.
metabolism system and also binds single-stranded DNA
and RNA with high affinity [27]. Nucleic acid binding
activity was also reported for other members of the family
[18]. The structure of Gal6 [19] represents one of the first
examples of an emerging class of self-compartmentalizing
proteases, along with the 20S proteasome [35]. The C ter-
minus of Gal6 lies in the active site and controls the activ-
ities of the enzyme including its unique ability to
inactivate bleomycin [22].
In solving the structure of human BH, we found a very
similar overall structure to that of the yeast form, as
expected from the sequence identity. However, the
central channel, which has a very prominent positive
charge in the yeast enzyme, is slightly negatively
charged in the human protein. Indeed, we have shown
that human BH does not have the DNA-binding activ-
ity of the yeast protein. This may reflect a somewhat
different or perhaps altered role in their respective bio-
logical functions. 
Recently, the clinical relevance of human BH has been
augmented by its possible association with Alzheimer’s
disease. The structure suggests that the location of a
putative disease-linked variation could affect interactions
with another protein, which in turn may modulate the
peptidase activity of human BH by repositioning the
C terminus. If indeed there is an involvement of human
BH in some Alzheimer’s disease pathology, the struc-
tural and functional similarities and differences between
the yeast and human forms may prove useful in delineat-
ing the disease mechanism. In addition, the structure of
human BH may now serve as a basis for the rational
design of inhibitors of BH activity to augment the effec-
tiveness of bleomycin in cancer treatment.
Materials and methods
Protein expression and purification
The gene encoding hBH was kindly provided by Carlos López-Otín at
the Universidad de Oviedo [17]. The gene fragment was isolated by
the polymerase chain reaction (PCR) using two oligonucleotides (the
5′ primer is 5′-GGCAGCGTGGGCGCCATGAGCAGCTC-3′ and
the 3′ primer is 5′-CGCGGATCCAGTATCACTCAGCCAAAGC-3′)
and digested using Nar I and Bam HI. The resulting fragment was
cloned into the bacterial expression vector pKH260. This vector is
the same as pKM260, which has been previously described [22],
with the exception that a 1kb Bgl II–Bsm I fragment in the tetR gene
was deleted to eliminate four Nar I sites. This vector produces an
expressed protein construct in which a six-histidine tag is attached 
to the N terminus of the protein via a tobacco etch virus protease 
(TEV) cleavage site. The Cys73→Ser/∆Glu455 double mutant was
made using a procedure similar to that previously described. Briefly,
the active-site cysteine was changed to serine by site-
directed mutagenesis using two complementary oligonucleotides
(5′-GAGCTCAGGGCGATCGTGGATCTTTTCTTGTC-3′ and 5′-
GACAAGAAAAGATCCACGATCGCCCTGAGCTC-3′). Then Glu455
was deleted by PCR using the 5′ primer and the deletion oligonu-
cleotides (5′-CGGGATCCGTATCAAGCCAAAGCTCCCATGGG-3′).
The gene encoding the double mutant was cloned into pKH260 and
the full length of the gene has been sequenced to confirm the
mutation. The vectors were transformed into E. coli strain BL21 with
pLysS for protein expression. The cells were grown in Luria broth
(LB) to mid-log phase (OD600 ~0.45) then hBH production was
induced with 200 µM isopropyl-β-D-thiogalactosyl pyranoside (IPTG).
The cells were grown for a further 5 h and then harvested, resus-
pended in 50 mM Na phosphate (pH 8.5), 300 mM NaCl, 7 mM
β-mercaptoethanol and frozen overnight at –80°C. 300 µl Triton-X-
100 and 15 µl β-mercaptoethanol were added per liter of culture and
the cells were thawed at room temperature, sonicated and cen-
trifuged. hBH was purified from the cell-free extract with a combina-
tion of nickel affinity, ion exchange and gel-filtration chromatography.
The gel-filtration step also served to exchange the buffer to that used
during crystallization. The protein was concentrated using a Millipore
ultrafree centrifugal filter to 30–50 mg/ml and stored at 4°C. The his-
tidine-tag was not removed.
Protease assays
To assay protease activity, hydrolysis of the fluorogenic substrates cit-
rulline-aminomethyl coumarylamide (H.Cit-AMC; Bachem), and argi-
nine-aminomethyl coumarylamide (H.Arg-AMC; Bachem) were
measured using a modified version of the Gal6p protease assay as
described by Xu and Johnston [13]. In these assays, 100 ng hBH or
the Cys73→Ser/∆Glu455 mutant protein were incubated in protease
assay buffer (200 mM KH2PO4, 200 mM Na2HPO4, 8 mM EDTA,
pH 7.5) for 10 min at 37°C. Each sample was contained within a final
volume of 40 µl in black-wall 96 well microtiter plates (Corning). To ini-
tiate the reactions, either of the fluorogenic substrates was added to a
final concentration of 1 µM. Reactions were monitored for a period of
2 h in an HTS 7000 plus bioassay reader (Perkin Elmer). Liberated
aminomethyl coumarin fluorescence was measured by excitation at a
wavelength of 360 nm and emission at 465 nm. Sample points within
the linear range of the assay were used for analysis. Formation of prod-
ucts was calculated from a standard curve of 7-amino-4-methyl-
coumarin (Bachem) fluorescence. Activity is defined as the amount
(pmol) of aminomethyl coumarin released from the substrate × mg–1
protein × min–1. Values for hBH activity were 152.0 and 33.1 on H.Cit-
AMC and H.Arg-AMC, respectively. No peptidase activity was exhibited
by the Cys73→Ser/∆Glu455 mutant on either substrate.
Crystallization and data collection
Human BH crystallized in a range of conditions from 16–20% PEG
10 K and pH 7–8.5. Crystallization was carried out at 17°C by the
hanging-drop vapor diffusion method. Drops were prepared by mixing
1 µl of well solution with 1 µl of protein solution (12 mg/ml in 25 mM
Tris, pH 8.0, 5% glycerol, 140 mM KCl and 1 mM DTT). The protein ini-
tially formed a precipitate that dissolved over a number of days and
from which the crystals grew. The mutant protein formed crystals in
space groups C2221 and R32; data have been collected for the wild-
type protein in space group C2221.
Data were collected at the National Synchrotron Light Source
(NSLS) on beamlines X26C and X25 on MAR imaging plates
(300 mm at X26C and a 345 mm at X25) using cryocrystallography
techniques. Crystals were soaked in a cryoprotectant solution (well
solution plus 30% ethylene glycol), mounted on loops and frozen
directly into the nitrogen stream. The reflection intensities were inte-
grated and scaled with the HKL [36] suite of programs. Each data
set was collected from a single crystal. In the case of the mutant
protein, two data sets were collected from the same crystal at resolu-
tion ranges of 30–3.0 Å and 3.5–1.85 Å to avoid saturation of the
high intensity low-angle reflections. Data for the wild-type protein
extended to 2.59 Å.
Solution and refinement
A polyalanine model was generated based on the structure of Gal6
with appropriate deletions and insertions made where the sequences
diverged. A trimer of this model, based on half the hexameric structure
of the yeast protein was used to solve the wild-type C2221 crystal by
molecular replacement using the program AMoRe [37]. This gave a
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solution with an R factor of 0.478 and a correlation coefficient of
0.347. Crystallographic symmetry operations generated the biologically
relevant hexameric structure confirming the correctness of the solution.
The R32 structure was solved with a model which had been partially
rebuilt in the wild-type data set. In this case the search model used
consisted of two independent monomers. The 32 crystallographic sym-
metry generates a hexamer from each of the two monomers in the
asymmetric unit.
Model-building was carried out using the program O [38] and refine-
ment using CNS [39] with a maximum-likelihood target function [40]
and a flat bulk-solvent correction. No σ cut-off was applied to the data.
Noncrystallographic symmetry (NCS) constraints were used for the
wild-type data which refined to an Rcryst of 0.238 and Rfree of 0.261. In
the final stages of refinement of the mutant data set, NCS restraints
were released and after the inclusion of alternate sidechain conforma-
tions for 15 residues (seven in molecule A and eight in molecule B) and
563 water molecules, the Rcryst and Rfree reached 0.182 and 0.210,
respectively. The electron-density maps are essentially complete,
except for the extreme N terminus containing the histidine-tag and
linker for which no density can be seen, and the loop from residues
383–387, for which the density is difficult to interpret. A Fo–Fc omit
map for the 440’s loop region is shown in Figure 6. The published
sequence has a tyrosine at position 280, which we found to be a histi-
dine. This could either be a variant, from the source or through propa-
gation, or there could have been a sequencing error. The DNA
sequence varies only by one base. This residue is on the surface of the
protein and therefore this difference should not have a significant effect
on the structure.
Gel mobility shift assays
Nucleic acid binding properties of BH in wild-type yeast and HeLa cell
extracts were examined by gel mobility shift assays, as described previ-
ously [13], with a modification in the sequence of the single-stranded
oligonucleotide used (5′-AGCTTAGCGGAAATTTGTGGTCGCA-3′). In
addition, 150 ng recombinant Gal6 was added to the HeLa extracts in a
mixing experiment. The presence of hBH in whole cell extracts was veri-
fied by western blot analysis using purified anti-hBH IgG generated in
rabbits. In order to compare the nucleic acid binding properties in human
and yeast whole cell extracts, equivalent amounts of hBH and Gal6 pro-
tease activity were included in the binding reaction. Specific hBH or Gal6
activity was recorded as the amount of protease activity in each extract
that was capable of being inhibited by the cysteine protease specific
inhibitor L-trans-epoxysuccinyl-leucylamide-(4-guanido)-butane (E64;
Sigma). Relative specific activity in extracts was defined as units of
E64-inhibitable protease activity × min–1 × mg protein–1.
Antibody purification and immunolocalization
Polyclonal hBH antibody was raised in rabbits immunized with recombi-
nant hBH. IgG was purified from crude serum using a protein A column
(Pierce). Affinity purification of anti-hBH antibody from the IgG was per-
formed using highly purified hBH protein. HeLa cells were seeded at a
density of 1–3 × 104 per chamber in a glass chamber slide (Nunc). For
immunofluorescence staining, cells were washed twice in phosphate
buffered saline (PBS) and fixed in a 4% para-formaldehyde PBS solu-
tion. Cells were washed twice and fixation was stopped by the addition
of 100 mM ammonium chloride PBS. Cells were then permeabilized by
incubation in 0.1% Triton X100-PBS, washed twice and blocked in 1%
bovine serum albumin (BSA) in PBS. Primary antibody incubations
were performed overnight at 4°C and were followed by three washes in
0.08% BSA/0.01% saponin in PBS (wash buffer). Secondary antibody
incubations were carried out with fluorescein-conjugated goat anti-
rabbit IgG (Pierce) for 2 h at room temperature. Slide chambers were
then washed three times in wash buffer, twice in PBS and six times in
filter-sterilized distilled water. Slides were air-dried and covered with
vectashield (Vector Laboratories). Images were captured using a Leitz
Laborlux-S epifluorescent photomicroscope possessing an Optronics
V1470 CCD array camera as well as Signal Analytics IP lab spectrum
capture and analysis software.
Accession numbers
The atomic coordinates of the wild-type and mutant hBH structures
have been deposited in the Protein Data Bank with accession numbers
1cb5 and 2cb5, respectively.
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Figure 6
Stereoview Fo–Fc omit map for residues
441–447 of the Cys73→Ser/∆Glu455
mutant of hBH, with the final structure
superimposed. The map is contoured at 3σ
and shows the quality of the structure in the
region of the AD-linked allelic variation.
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